|
1
|
Hu Z, Fan C, Oh DS, Marron JS, He X,
Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The
molecular portraits of breast tumors are conserved across
microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Brien KM, Cole SR, Tse CK, Perou CM,
Carey LA, Foulkes WD, Dressler LG, Geradts J and Millikan RC:
Intrinsic breast tumor subtypes, race, and long-term survival in
the Carolina Breast Cancer Study. Clin Cancer Res. 16:6100–6110.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rilke F, Colnaghi MI, Cascinelli N,
Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S,
Pierotti MA and Testori A: Prognostic significance of HER-2/neu
expression in breast cancer and its relationship to other
prognostic factors. Int J Cancer. 49:44–49. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cronin KA, Harlan LC, Dodd KW, Abrams JS
and Ballard-Barbash R: Population-based estimate of the prevalence
of HER-2 positive breast cancer tumors for early stage patients in
the US. Cancer Invest. 28:963–968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alroy I and Yarden Y: The ErbB signaling
network in embryogenesis and oncogenesis: Signal diversification
through combinatorial ligand-receptor interactions. FEBS Lett.
410:83–86. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rubin I and Yarden Y: The basic biology of
HER2. Ann Oncol. 12 (Suppl 1):S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferreira PMP and Pessoa C: Molecular
biology of human epidermal receptors, signaling pathways and
targeted therapy against cancers: new evidences and old challenges.
Braz J Pharm Sci. 53:1–17. 2017. View Article : Google Scholar
|
|
8
|
Harris L, Fritsche H, Mennel R, Norton L,
Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American
Society of Clinical Oncology, : American Society of Clinical
Oncology 2007 update of recommendations for the use of tumor
markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al American Society of Clinical Oncology; College
of American Pathologists, : Recommendations for human epidermal
growth factor receptor 2 testing in breast cancer: American Society
of Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Noone AM, Cronin KA, Altekruse SF,
Howlader N, Lewis DR, Petkov VI and Penberthy L: Cancer Incidence
and Survival Trends by Subtype Using Data from the Surveillance
Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol
Biomarkers Prev. 26:632–641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human Epidermal Growth Factor Receptor 2 Testing in
Breast Cancer: American Society of Clinical Oncology/College of
American Pathologists Clinical Practice Guideline Focused Update. J
Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Allison KH, Hammond MEH, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and Progesterone
Receptor Testing in Breast Cancer: American Society of Clinical
Oncology/College of American Pathologists Guideline Update. Arch
Pathol Lab Med. 144:545–563. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Filipits M, Rudas M, Singer CF, Fitzal F,
Bago-Horvath Z, Greil R, Balic M, Lax SF, Halper S, Hulla W, et al:
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women
with hormone receptor-positive early breast cancer: Results from
ABCSG Trial 6. ESMO Open. 6:1002282021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Révillion F, Lhotellier V, Hornez L,
Bonneterre J and Peyrat JP: ErbB/HER ligands in human breast
cancer, and relationships with their receptors, the
bio-pathological features and prognosis. Ann Oncol. 19:73–80. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smith BL, Chin D, Maltzman W, Crosby K,
Hortobagyi GN and Bacus SS: The efficacy of Herceptin therapies is
influenced by the expression of other erbB receptors, their ligands
and the activation of downstream signalling proteins. Br J Cancer.
91:1190–1194. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Motoyama AB, Hynes NE and Lane HA: The
efficacy of ErbB receptor-targeted anticancer therapeutics is
influenced by the availability of epidermal growth factor-related
peptides. Cancer Res. 62:3151–3158. 2002.PubMed/NCBI
|
|
18
|
Vernieri C, Milano M, Brambilla M,
Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L,
Mariani G, et al: Resistance mechanisms to anti-HER2 therapies in
HER2-positive breast cancer: Current knowledge, new research
directions and therapeutic perspectives. Crit Rev Oncol Hematol.
139:53–66. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong ALA and Lee SC: Mechanisms of
Resistance to Trastuzumab and Novel Therapeutic Strategies in
HER2-Positive Breast Cancer. Int J Breast Cancer. 2012:4151702012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Luo XX, Tang YL, Xu JX and Zeng
ZG: The prognostic values of insulin-like growth factor binding
protein in breast cancer. Medicine (Baltimore). 98:e155612019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen C, Zhao KN, Masci PP, Lakhani SR,
Antonsson A, Simpson PT and Vitetta L: TGFβ isoforms and receptors
mRNA expression in breast tumours: Prognostic value and clinical
implications. BMC Cancer. 15:10102015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heublein S, Mayr D, Meindl A, Angele M,
Gallwas J, Jeschke U and Ditsch N: Thyroid Hormone Receptors
Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing
Ways. PLoS One. 10:e01270722015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ditsch N, Toth B, Himsl I, Lenhard M,
Ochsenkühn R, Friese K, Mayr D and Jeschke U: Thyroid hormone
receptor (TR)alpha and TRbeta expression in breast cancer. Histol
Histopathol. 28:227–237. 2013.PubMed/NCBI
|
|
24
|
Hua S, Kittler R and White KP: Genomic
antagonism between retinoic acid and estrogen signaling in breast
cancer. Cell. 137:1259–1271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ross-Innes CS, Stark R, Holmes KA, Schmidt
D, Spyrou C, Russell R, Massie CE, Vowler SL, Eldridge M and
Carroll JS: Cooperative interaction between retinoic acid
receptor-alpha and estrogen receptor in breast cancer. Genes Dev.
24:171–182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Razis E, Bobos M, Kotoula V, Eleftheraki
AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos
G, Efstratiou I, et al: Evaluation of the association of PIK3CA
mutations and PTEN loss with efficacy of trastuzumab therapy in
metastatic breast cancer. Breast Cancer Res Treat. 128:447–456.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fountzilas G, Christodoulou C, Bobos M,
Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A,
Pentheroudakis G, Xiros N, Papaspirou I, et al: Topoisomerase II
alpha gene amplification is a favorable prognostic factor in
patients with HER2-positive metastatic breast cancer treated with
trastuzumab. J Transl Med. 10:2122012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koumarianou A, Karayannopoulou G,
Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D,
Galani E, Pentheroudakis G, Pectasides D, et al: PAI-1 and HER2
interaction in advanced breast cancer disease: Evidence for added
benefit from trastuzumab in HER2-negative patients. Cancer
Chemother Pharmacol. 75:1289–1301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al American Society of Clinical Oncology; College of American
Pathologists, : American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pavlakis K, Bobos M, Batistatou A, Kotoula
V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G,
Psyrri A, Koutras A, et al: p85 protein expression is associated
with poor survival in HER2-positive patients with advanced breast
cancer treated with trastuzumab. Pathol Oncol Res. 21:273–282.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gogas H, Kotoula V, Alexopoulou Z,
Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E,
Tsolaki E, Xanthakis I, et al: MYC copy gain, chromosomal
instability and PI3K activation as potential markers of
unfavourable outcome in trastuzumab-treated patients with
metastatic breast cancer. J Transl Med. 14:1362016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Christodoulou C, Oikonomopoulos G, Koliou
GA, Kostopoulos I, Kotoula V, Bobos M, Pentheroudakis G, Lazaridis
G, Skondra M, Chrisafi S, et al: Evaluation of the Insulin-like
Growth Factor Receptor Pathway in Patients with Advanced Breast
Cancer Treated with Trastuzumab. Cancer Genomics Proteomics.
15:461–471. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al International TILs Working Group 2014, :
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast
cancer: Recommendations by an International TILs Working Group
2014. Ann Oncol. 26:259–271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sauter G, Lee J, Bartlett JM, Slamon DJ
and Press MF: Guidelines for human epidermal growth factor receptor
2 testing: Biologic and methodologic considerations. J Clin Oncol.
27:1323–1333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Economopoulou P, Kotoula V, Koliou GA,
Papadopoulou K, Christodoulou C, Pentheroudakis G, Lazaridis G,
Arapantoni-Dadioti P, Koutras A, Bafaloukos D, et al: Prognostic
Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast
Cancer Patients Treated with Trastuzumab. Transl Oncol. 12:739–748.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Perez EA, Suman VJ, Davidson NE, Martino
S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D and
Jenkins RB: HER2 testing by local, central, and reference
laboratories in specimens from the North Central Cancer Treatment
Group N9831 intergroup adjuvant trial. J Clin Oncol. 24:3032–3038.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roche PC, Suman VJ, Jenkins RB, Davidson
NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN and Perez
EA: Concordance between local and central laboratory HER2 testing
in the breast intergroup trial N9831. J Natl Cancer Inst.
94:855–857. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Paik S, Bryant J, Tan-Chiu E, Romond E,
Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, et al:
Real-world performance of HER2 testing - National Surgical Adjuvant
Breast and Bowel Project experience. J Natl Cancer Inst.
94:852–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaufman PA, Bloom KJ, Burris H, Gralow JR,
Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, et al:
Assessing the discordance rate between local and central HER2
testing in women with locally determined HER2-negative breast
cancer. Cancer. 120:2657–2664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Perez EA, Cortés J, Gonzalez-Angulo AM and
Bartlett JM: HER2 testing: Current status and future directions.
Cancer Treat Rev. 40:276–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fehrenbacher L, Cecchini RS, Geyer CE Jr,
Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau
JF, Provencher L, et al: NSABP B-47/NRG Oncology Phase III
Randomized Trial Comparing Adjuvant Chemotherapy With or Without
Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2
by FISH and With IHC 1+ or 2. J Clin Oncol. 38:444–453. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Exman P and Tolaney SM: HER2-positive
metastatic breast cancer: A comprehensive review. Clin Adv Hematol
Oncol. 19:40–50. 2021.PubMed/NCBI
|
|
43
|
Fiszman GL and Jasnis MA: Molecular
Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast
Cancer. Int J Breast Cancer. 2011:3521822011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sergina NV and Moasser MM: The HER family
and cancer: Emerging molecular mechanisms and therapeutic targets.
Trends Mol Med. 13:527–534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Britsch S: The neuregulin-I/ErbB signaling
system in development and disease. Adv Anat Embryol Cell Biol.
190:1–65. 2007.PubMed/NCBI
|
|
46
|
Seoane S, Montero JC, Ocaña A and
Pandiella A: Breast cancer dissemination promoted by a
neuregulin-collagenase 3 signalling node. Oncogene. 35:2756–2765.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang L, Li Y, Shen E, Cao F, Li L, Li X,
Wang X, Kariminia S, Chang B, Li H, et al: NRG1-dependent
activation of HER3 induces primary resistance to trastuzumab in
HER2-overexpressing breast cancer cells. Int J Oncol. 51:1553–1562.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Schwarz LJ, Hutchinson KE, Rexer BN,
Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano
L, Guerrero-Zotano A, Red-Brewer M, et al: An ERBB1-3 Neutralizing
Antibody Mixture With High Activity Against Drug-Resistant HER2+
Breast Cancers With ERBB Ligand Overexpression. J Natl Cancer Inst.
109:djx0652017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rimawi MF: EGFR Expression in Breast
Cancer Association with biologic phenotype and clinical outcomes.
Cancer. 116:1234–1242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ross JS and Fletcher JA: The HER-2/neu
Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor,
and Target for Therapy. Oncologist. 3:237–252. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Robinson AG, Turbin D, Thomson T, Yorida
E, Ellard S, Bajdik C, Huntsman D and Gelmon K: Molecular
predictive factors in patients receiving trastuzumab-based
chemotherapy for metastatic disease. Clin Breast Cancer. 7:254–261.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kudlow JE, Cheung CY and Bjorge JD:
Epidermal growth factor stimulates the synthesis of its own
receptor in a human breast cancer cell line. J Biol Chem.
261:4134–4138. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cheng H, Ballman K, Vassilakopoulou M,
Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE,
Fountzilas G, et al: EGFR expression is associated with decreased
benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J
Cancer. 111:1065–1071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ali R and Wendt MK: The paradoxical
functions of EGFR during breast cancer progression. Signal
Transduct Target Ther. 2:160422017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wendt MK, Williams WK, Pascuzzi PE,
Balanis NG, Schiemann BJ, Carlin CR and Schiemann WP: The
Antitumorigenic Function of EGFR in Metastatic Breast Cancer is
Regulated by Expression of Mig6. Neoplasia. 17:124–133. 2015.
View Article : Google Scholar : PubMed/NCBI
|
